{"schema_version":"secwatch.filing_event.v1","accession":"0001420720-24-000018","form_type":"8-K","ticker":"IBIO","cik":"0001420720","company_name":"iBio, Inc.","filed_at":"2024-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.342443+00:00","generated_at":"2026-06-02T02:08:01.879684+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"iBio Q3 net loss $2.6M; cash raised to $17.9M via PIPE; enters AstralBio collaboration","bullets":["Net loss from continuing ops: $2.6M ($0.71/share) vs $6.3M ($9.53/share) YoY; no revenue.","R&D expenses down 66%, G&A down 23% YoY under cash preservation strategy.","Cash and equivalents $17.9M after $15M PIPE closed in April, up from $6.4M at March 31.","Partnered with AstralBio to develop 4 antibody targets for obesity/cardiometabolic diseases.","Sold early-stage PD-1 asset to Otsuka for $1M upfront and up to $52.5M in contingent payments."],"urls":{"canonical":"https://secwatch.observer/filing/0001420720-24-000018","json":"https://secwatch.observer/filing/0001420720-24-000018.json","markdown":"https://secwatch.observer/filing/0001420720-24-000018.md","text":"https://secwatch.observer/filing/0001420720-24-000018.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1420720/000142072024000018/0001420720-24-000018-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1420720/000142072024000018/ibio-20240513x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T02:08:01.879684+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4af20ee1212125d2aa40f1f7a73cd49d11f428e1","claim":"iBio, Inc. reported financial results for third quarter ended March 31, 2024.","evidence_excerpt":"On May 13, 2024, iBio, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1420720/000142072024000018/0001420720-24-000018-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}